Repligen Co. (NASDAQ:RGEN – Free Report) – Investment analysts at William Blair raised their Q4 2024 earnings estimates for Repligen in a research note issued on Tuesday, July 30th. William Blair analyst M. Larew now anticipates that the biotechnology company will post earnings of $0.50 per share for the quarter, up from their previous estimate of $0.47. The consensus estimate for Repligen’s current full-year earnings is $1.44 per share.
Repligen (NASDAQ:RGEN – Get Free Report) last issued its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.33 EPS for the quarter, meeting the consensus estimate of $0.33. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The company had revenue of $154.07 million during the quarter, compared to analysts’ expectations of $154.11 million. During the same quarter in the previous year, the company earned $0.53 earnings per share. Repligen’s revenue for the quarter was down 3.2% on a year-over-year basis.
View Our Latest Report on Repligen
Repligen Price Performance
RGEN stock opened at $161.67 on Thursday. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.35 and a quick ratio of 5.24. Repligen has a one year low of $110.45 and a one year high of $211.13. The stock has a market cap of $9.06 billion, a PE ratio of 646.71, a P/E/G ratio of 5.65 and a beta of 0.95. The firm has a 50 day simple moving average of $134.92 and a two-hundred day simple moving average of $166.05.
Insiders Place Their Bets
In other Repligen news, VP Ralf Kuriyel sold 4,465 shares of the stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $165.67, for a total transaction of $739,716.55. Following the completion of the sale, the vice president now directly owns 19,261 shares of the company’s stock, valued at approximately $3,190,969.87. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, CEO Anthony Hunt sold 20,072 shares of the firm’s stock in a transaction on Tuesday, May 21st. The shares were sold at an average price of $168.26, for a total value of $3,377,314.72. Following the completion of the transaction, the chief executive officer now directly owns 163,177 shares of the company’s stock, valued at $27,456,162.02. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Ralf Kuriyel sold 4,465 shares of the firm’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $165.67, for a total transaction of $739,716.55. Following the completion of the transaction, the vice president now directly owns 19,261 shares of the company’s stock, valued at $3,190,969.87. The disclosure for this sale can be found here. 1.20% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of RGEN. YHB Investment Advisors Inc. purchased a new position in Repligen during the first quarter worth $26,000. International Assets Investment Management LLC purchased a new position in Repligen during the second quarter worth $33,000. Lazard Asset Management LLC boosted its stake in Repligen by 206.1% during the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after buying an additional 136 shares during the period. Benjamin F. Edwards & Company Inc. boosted its stake in Repligen by 152.1% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock worth $43,000 after buying an additional 146 shares during the period. Finally, Principal Securities Inc. bought a new stake in shares of Repligen during the fourth quarter worth $48,000. 97.64% of the stock is owned by hedge funds and other institutional investors.
Repligen Company Profile
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Featured Stories
- Five stocks we like better than Repligen
- What to Know About Investing in Penny Stocks
- Should You Invest in Bitcoin? Pros and Cons
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Amazon Stock is Primed to Rebound Strongly After AI Bubble Bursts
- Are Penny Stocks a Good Fit for Your Portfolio?
- Shell Stock: Oil & Gas Giant Committed to Buybacks and Dividends
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.